Seeking Alpha

KarinCA's  Instablog

Send Message
I'm an independent writer/trader/investor whose primary interests are in the stem cell and biotech arena. My secondary interest is in oil/energy speculation. I do venture elsewhere at times. There’s an option to follow me at the top of any article I write. Click it and you’ll also see an option... More
View KarinCA's Instablogs on:
  • $CTIX - My Visit To Cellceutix, The Biotech That A Short Seller Recently Called A Sham

    The following article is a must read for those that have doubts about the existence of Cellceutix offices after the publishing of a hit peice:

    $CTIX - My visit to Cellceutix, the biotech that a short seller recently called a sham

    The two took me on a tour of the 12,000 square foot facility, including the labs, where I saw three people who appeared to be researchers. The company as a whole has just 14 employees, some of whom do not work onsite, as they are involved in the company's clinical trials at Dana-Farber and Brigham and Women's Hospital. According to the federal website that tracks clinical trials, the company has conducted a total of five trials, three of which are ongoing.

    I've also interviewed the CEO several times and the interviews are published here on Seeking Alpha. Following is a link to the most recent interview:

    The next link is to the interview following the purchase of the PolyMedix assets out of bankruptcy:

    As a side note, I'm a bit tired of hearing about Dr Menon's degree. Dr Menon didn't create the bio stating his degree was from Harvard. The original mistake was copied all over the internet. Whomever created the bio on the nnvc site copied it just like everyone else did. Amazingly, even ctix copied it incorrectly when they copied and pasted from the nnvc site for expediency. It was corrected once pointed out.

    CTIX has actually been moving science forward as can be seen here:

    Follow the science. The company has been excellent in moving the trials forward. Especially, the Brilacidin phase IIb. It's wasn't long after they picked up the PolyMedix assets before Dr Menon figured out how to optimize the dosing to avoid the issues the Polymedix phase IIa ran into. The excellent results in the ABSSSI phase IIb trial show it was the correct move. The picking up of those assets and figuring out how to mine them for the gold was quite brilliant.

    The Kevetrin phase I trial has been very slow, but, that's not the companies fault. Dana Farber is running the trial and the patients are stage 4 cancer patients. They must be treated with care. Oncology trials just run slow. Sadly… for the patients that might like to try the drug asap.

    Overall, I'm impressed with how well management as moved the science forward.

    Tags: CTIX
    Aug 14 2:55 PM | Link | 2 Comments
  • US Army Adopts And Deploys Provodine® From Microdermis To Fight Ebola

    This new anti-infective will end up preventing a lot of healthcare workers from contracting Ebola. It's a step in the right direction.

    "The antiseptic skin product, Provodine®, is being applied as a final "molecular barrier" to viral exposure for healthcare workers and emergency responders using traditional layers of protective equipment. To date a total of 335 relief workers have died while fighting to prevent the transmission of Ebola virus infections in West Africa. Skin coverage is an issue. Unlike most branded antiseptic products - which are contra-indicated for eye, mucosal surfaces (nose and mouth), ear and genitals - Provodine® can be safely used on the most sensitive areas of the body."

    Too bad the company is privately held. I wonder how many mistake this product for a cure?

    Dec 01 3:50 PM | Link | 1 Comment
  • Four “Ebola” Related Companies Suspended By SEC

    SEC files Order of Suspension of Trading of the following companies:

    Bravo Enterprises Ltd. OGNG

    Immunotech Laboratories, Inc. IMMB

    Myriad Interactive Media, Inc. MYRY

    Wholehealth Products, Inc. GWPC

    Nov 21 11:17 AM | Link | Comment!
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.